OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
Julia Hambach, William Fumey, Tobias Stähler, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Julia Hambach, William Fumey, Tobias Stähler, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Showing 14 citing articles:
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
Antonio Tapia‐Galisteo, Marta Compte, Luís Álvarez-Vallina, et al.
Theranostics (2023) Vol. 13, Iss. 3, pp. 1028-1041
Open Access | Times Cited: 45
Antonio Tapia‐Galisteo, Marta Compte, Luís Álvarez-Vallina, et al.
Theranostics (2023) Vol. 13, Iss. 3, pp. 1028-1041
Open Access | Times Cited: 45
Nanobodies: Robust miniprotein binders in biomedicine
Jeffrey Yong Joon Kim, Zhe Sang, Yufei Xiang, et al.
Advanced Drug Delivery Reviews (2023) Vol. 195, pp. 114726-114726
Open Access | Times Cited: 43
Jeffrey Yong Joon Kim, Zhe Sang, Yufei Xiang, et al.
Advanced Drug Delivery Reviews (2023) Vol. 195, pp. 114726-114726
Open Access | Times Cited: 43
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years
Elena Alexander, Kam W. Leong
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Elena Alexander, Kam W. Leong
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
An Zhu, Yu Bai, Yanyang Nan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 5
An Zhu, Yu Bai, Yanyang Nan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 5
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Natural killer cell engagers for cancer immunotherapy
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
CD38 as theranostic target in oncology
Valentina Bassareo, Jessica Bridoux, Puchowicz Michelle, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Valentina Bassareo, Jessica Bridoux, Puchowicz Michelle, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas
Kristen D. Pawlowski, Joseph Duffy, Arushi Tiwari, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1716-1716
Open Access | Times Cited: 8
Kristen D. Pawlowski, Joseph Duffy, Arushi Tiwari, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1716-1716
Open Access | Times Cited: 8
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
Huan Tian, Bugao Guan, Hongbo Li, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Huan Tian, Bugao Guan, Hongbo Li, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Single-Domain Antibodies—Novel Tools to Study and Treat Allergies
Ines Zettl, Clarissa Bauernfeind, Jessica Kollárová, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7602-7602
Open Access | Times Cited: 1
Ines Zettl, Clarissa Bauernfeind, Jessica Kollárová, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7602-7602
Open Access | Times Cited: 1
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Luca Julius Pape, Julia Hambach, Anna Josephine Gebhardt, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Luca Julius Pape, Julia Hambach, Anna Josephine Gebhardt, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
Julia Hambach, Anna Marei Mann, Peter Bannas, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Julia Hambach, Anna Marei Mann, Peter Bannas, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Encapsulation of anti-VEGF nanobody into niosome nanoparticles: a novel approach to enhance circulation half life and efficacy
Mohsen Chiani, Raha Abedini, Reza Ahangari-Cohan, et al.
Journal of Microencapsulation (2024), pp. 1-10
Closed Access
Mohsen Chiani, Raha Abedini, Reza Ahangari-Cohan, et al.
Journal of Microencapsulation (2024), pp. 1-10
Closed Access
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma
Sarah A. Holstein
Hematology (2022) Vol. 2022, Iss. 1, pp. 173-179
Open Access | Times Cited: 1
Sarah A. Holstein
Hematology (2022) Vol. 2022, Iss. 1, pp. 173-179
Open Access | Times Cited: 1
